CRNX - クリネティック・ファ―マシュ―ティカルズ （Crinetics Pharmaceuticals Inc.） クリネティック・ファ―マシュ―ティカルズCRNXのチャート
CRNXの企業情報
| symbol | CRNx |
|---|---|
| 会社名 | Crinetics Pharmaceuticals Inc （クリネティック・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 クリネティクス・ファーマスーティカル（Crinetics Pharmaceuticals Inc.）は臨床段階の製薬会社である。同社は、特殊内分泌疾患と内分泌関連腫瘍を治療するための薬物の発見及び開発に注力する。同社は、内分泌疾患の治療のためにペプチドGタンパク質共役受容体（GPCR）を標的とする経口非ペプチド化学物質のパイプラインを開発する。同社のリード製品候補は、先端巨大症の治療用に開発されるCRN00808である。また、高インスリン血症のCRN02481と、神経内分泌腫瘍の治療のためのCRN01941の2種類の製品候補を開発する。CRN02481とCRN01941は、発達の前臨床段階にある経口非ペプチド性ソマスタチン受容体である。同社はまた、クッシング病の治療のための非ペプチド製品の開発に関する研究プログラムを実施する。 クリネティック・ファ―マシュ―ティカルズは米国の医薬品企業。臨床段階で、内分泌疾患や内分泌系腫瘍の治療薬の開発・商業化に従事する。同社の候補薬CRN00808は先端巨大症の治療、CRN02481は先天性高インスリン症の治療、またCRN01941は神経内分泌腫瘍の治療に使用される。本社所在地はカリフォルニア州サンディエゴ。 Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company |
| 本社所在地 | 10222 Barnes Canyon Road Bldg. #2 San Diego CA 92121 USA |
| 代表者氏名 | Wendall Wierenga Wendall Wierenga |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 858-450-6464 |
| 設立年月日 | 39753 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 36人 |
| url | www.crinetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/crnx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -15.88400 |
| 終値（lastsale） | 23.52 |
| 時価総額（marketcap） | 565049913.12 |
| 時価総額 | 時価総額（百万ドル） 560.24510 |
| 売上高 | 売上高（百万ドル） 2.26700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 491.83910 |
| 当期純利益 | 当期純利益（百万ドル） -15.93500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Crinetics Pharmaceuticals Inc revenues increased 25% to $1.1M. Net loss increased from $4.3M to $11M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase from $4.1M to $9.7M (expense) General and administrative - Balancing v increase from $913K to $2M (expense). |
CRNXのテクニカル分析
CRNXのニュース
CRNX stock falls as FDA rejects Phase 2 study for hyperinsulinism drug (NASDAQ:CRNX) 2022/11/28 16:03:17 Seeking Alpha
Clinical-stage biotech Crinetics Pharmaceuticals (CRNX) announced Monday that the FDA did not greenlight its investigational new drug application ((IND)) for the Phase 2 clinical study…
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference 2022/11/22 13:00:00 Wallstreet:Online
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29 – December 1, 2022. Details of the Crinetics fireside chat are as follows: Date & Time:
Thinking Of Investing In Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Stock? Here’s What You Need To Know 2022/11/19 18:00:00 Stocks Register
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) shares, rose in value on Friday, 11/18/22, with the stock price up by 1.42% to the previous day’s close as strong demand from buyers drove the stock to $17.83. Actively observing the price movement in the last trading, the stock closed the session at $17.58, falling within a range of $17.47 … Thinking Of Investing In Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Stock? Here’s What You Need To Know Read More »
Crinetics Pharmaceuticals GAAP EPS of -$0.78 beats by $0.03, revenue of $0.46M beats by $0.26M 2022/11/14 14:14:23 Seeking Alpha
Crinetics Pharmaceuticals press release (CRNX): Q3 GAAP EPS of -$0.78 beats by $0.03.Revenue of $0.46M beats by $0.26M.
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update 2022/11/14 13:00:00 GlobeNewswire
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer 2022/10/03 12:00:00 Benzinga
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (NASDAQ: CRNX ) today announced the appointment of Dana Pizzuti, M.D., as chief development officer. Dr. Pizzuti is a board-certified physician with more than 30 years of pharmaceutical industry experience in clinical development, pharmacovigilance, and medical and regulatory affairs. "Dr. Pizzuti''s expertise in working with global regulators to safely and effectively progress multiple programs through development and ultimately commercialization will serve us well as our extensive pipeline of internally discovered drug candidates advances," said Scott Struthers, Ph.D. , founder and chief executive officer of Crinetics. "Looking forward to 2023, Dr. Pizzuti''s wealth of experience will be especially valuable as we plan for topline data from our Phase 3 studies for paltusotine in acromegaly and we prepare marketing authorization applications." Dr. Pizzuti added, "Crinetics has constructed an impressive multi-asset pipeline, and it is an honor to be joining a company with such a robust discovery engine.
Crinetics Pharmaceuticals''s Return On Capital Employed Overview 2022/09/09 14:16:45 Benzinga
Benzinga Pro data, Crinetics Pharmaceuticals (NASDAQ: CRNX ) reported Q2 sales of $439 thousand. Earnings fell to a loss of $42.38 million, resulting in a 22.38% decrease from last quarter. Crinetics Pharmaceuticals collected $3.13 million in revenue during Q1, but reported earnings showed a $34.63 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is … Full story available on Benzinga.com
Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference 2022/09/08 12:00:00 GlobeNewswire
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24 th Annual Global Investment Conference being held September 12-14, 2022, both virtually and in-person at the Lotte New York Palace Hotel.
Crinetics Pharmaceuticals: Q2 Earnings Insights 2022/08/12 13:15:13 Benzinga
Crinetics Pharmaceuticals (NASDAQ: CRNX ) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Crinetics Pharmaceuticals missed estimated earnings by 20.9%, reporting an … Full story available on Benzinga.com
Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M 2022/08/12 12:28:28 Seeking Alpha
Crinetics Pharmaceuticals press release (CRNX): Q2 GAAP EPS of -$0.81 misses by $0.15.Revenue of $0.44M misses by $0.28M.Based on its current plans, the company expects that…
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2022/07/12 21:09:00 GlobeNewswire
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 12, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,500 shares of its common stock to six new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics: Late-Stage Acromegaly Disease Studies Will Be Inflection Point (NASDAQ:CRNX) 2022/06/13 20:19:41 Seeking Alpha
Two ongoing studies for use of paltusotine for treatment of patients with Acromegaly are PATHFNDR-1 and PATHFNDR-2. Read what this means for CRNX stock.
Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference 2022/06/07 11:30:00 GlobeNewswire
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in person in a fireside chat at the annual JMP Securities Life Sciences Conference, which is being held at the Lotte New York Palace on June 15-16, 2022.
Crinetics Pharmaceuticals Announces Positive Top-line Results From CRN04894 Early-Stage Trial 2022/05/25 13:11:13 Benzinga
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) revealed positive topline results from a first-in-human Phase 1 clinical study of CRN04894 for the treatment of patients with Cushing''s disease. CRN04894 is Crinetics’ first-in-class adrenocorticotropic hormone (ACTH) antagonist that is being investigated in the phase 1 study for the treatment of Cushing''s disease. Scott Struthers , Ph.D., founder and chief executive officer, said, “Due … Full story available on Benzinga.com